Batool F. Kirmani, K. Au, Seema Mir, M. Hogan, Dennis (Dong Hwan) Kim, Pushpa Sharma
{"title":"Biomarkers for epileptogenesis in patients with autoimmune epilepsy","authors":"Batool F. Kirmani, K. Au, Seema Mir, M. Hogan, Dennis (Dong Hwan) Kim, Pushpa Sharma","doi":"10.20517/2347-8659.2020.29","DOIUrl":null,"url":null,"abstract":"Autoimmune epilepsy (AE) is a general term to describe recurrent seizures that have an immune-mediated origin. It is increasingly being recognized as a cause of epilepsy due to accumulating evidence supporting an immunemediated pathogenesis in patients who have shown resistance to traditional antiepileptic drugs (AEDs). The diagnosis of AE is one of the exclusions. Currently, there are no strict diagnostic guidelines for AE, and it is similarly under-recognized. The importance of early diagnosis of AE cannot be overstated, as prompt immunotherapy is important for seizure reduction. Further investigations into potential biomarkers are needed for early detection of AE and include targeted immunotherapies in combination with AEDs. The goal of this review was to provide an overview of the following biomarkers that have been associated with AE: AMPAR, LGl1, CASPR2, DPPX, GABAAR, GABABR, GFAP, GlyR, mGluR5, NMDAR, VGCC (P/Q types), amphiphysin, ANNA-1, CRMP-5, GAD65, and Ma1/","PeriodicalId":19129,"journal":{"name":"Neuroimmunology and Neuroinflammation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology and Neuroinflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20517/2347-8659.2020.29","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Autoimmune epilepsy (AE) is a general term to describe recurrent seizures that have an immune-mediated origin. It is increasingly being recognized as a cause of epilepsy due to accumulating evidence supporting an immunemediated pathogenesis in patients who have shown resistance to traditional antiepileptic drugs (AEDs). The diagnosis of AE is one of the exclusions. Currently, there are no strict diagnostic guidelines for AE, and it is similarly under-recognized. The importance of early diagnosis of AE cannot be overstated, as prompt immunotherapy is important for seizure reduction. Further investigations into potential biomarkers are needed for early detection of AE and include targeted immunotherapies in combination with AEDs. The goal of this review was to provide an overview of the following biomarkers that have been associated with AE: AMPAR, LGl1, CASPR2, DPPX, GABAAR, GABABR, GFAP, GlyR, mGluR5, NMDAR, VGCC (P/Q types), amphiphysin, ANNA-1, CRMP-5, GAD65, and Ma1/
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
